IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.08
−1.34%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 21.64x
- P/S forward
- 32.05x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -8.18x
- Price / sales
- 51.65x
- Price / cash flow
- -24.02x
Enterprise value
- Enterprise value
- $9.0B
- EV / sales
- 54.41x
- EV / EBITDA
- -10.15x
- EV / EBIT
- -35.82x
- Market cap
- $8.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026